Jacobi Capital Management’s DMK Pharmaceuticals Corporation Common Stock DMK Stock Holding History

Jacobi Capital Management’s Portfolio DMK Stock Details DMK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-357	Closed	-$20K	–	1390
2020 Q3	$20K	Hold	357	–	–	﹤0.01%	678
2020 Q2	$13K	Hold	357	–	–	﹤0.01%	740
2020 Q1	$9K	Hold	357	–	–	﹤0.01%	732
2019 Q4	$18K	Hold	357	–	–	﹤0.01%	656
2019 Q3	$18K	Sell	357 -35	-9%	-$2.51K	﹤0.01%	643
2019 Q2	$36K	Buy	392 +357	+1,020%	+$43.4K	0.01%	502
2019 Q1	$5K	Hold	35	–	–	﹤0.01%	805
2018 Q4	$5K	Sell	35 -71	-67%	-$13.6K	﹤0.01%	771
2018 Q3	$26K	Hold	106	–	–	0.01%	534
2018 Q2	$24K	Hold	106	–	–	0.01%	547
2018 Q1	$25K	Hold	106	–	–	0.01%	524
2017 Q4	$35K	Hold	106	–	–	0.01%	442
2017 Q3	$39K	Sell	106 -37	-26%	-$13.1K	0.01%	388
2017 Q2	$56K	Hold	143	–	–	0.02%	290
2017 Q1	$46K	Hold	143	–	–	0.02%	260
2016 Q4	$34K	Buy	+143	New	+$28.7K	0.02%	262

Other funds holding DMK

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RVW Wealth Los Angeles, California $1.52B AUM 23.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Jacobi Capital Management's DMK Position: Q4 2020 in Review

Jacobi Capital Management sold out of DMK Pharmaceuticals Corporation Common Stock (DMK) in Q4 2020, closing a stake of 357 shares — an estimated $20K sold.

Jacobi Capital Management first reported a position in DMK in Q4 2016 and held it in 16 quarters. The position peaked at $56K in Q2 2017. 41 funds tracked by Wall St. Rank hold DMK as of Q4 2020.

Jacobi Capital Management reported no remaining DMK Pharmaceuticals Corporation Common Stock position as of Q4 2020 after selling out during the quarter.
Jacobi Capital Management sold 357 DMK Pharmaceuticals Corporation Common Stock shares in Q4 2020, an estimated $20K.
Jacobi Capital Management first reported a position in DMK Pharmaceuticals Corporation Common Stock in Q4 2016 and held it in 16 quarters.
Jacobi Capital Management's DMK Pharmaceuticals Corporation Common Stock position peaked at $56K in Q2 2017.
41 funds tracked by Wall St. Rank held DMK Pharmaceuticals Corporation Common Stock as of Q4 2020.

Based on Jacobi Capital Management's 13F filing for Q4 2020, filed 8 Feb 2021.